Fiore C E, Lunetta M, Kanis J A
Clin Endocrinol (Oxf). 1985 Sep;23(3):277-82. doi: 10.1111/j.1365-2265.1985.tb00224.x.
We assessed the effects of ranitidine and cimetidine (histamine H2-receptor antagonists) on the serum concentrations of parathyroid hormone (PTH) in 22 patients with end-stage chronic renal failure. Treatment for 3 months induced a significant decrease in serum concentrations of PTH determined by radioimmunoassay directed at the mid portion of the PTH molecule. In contrast, significant increases were noted using an assay directed at the amino-terminal portion, whereas no change was noted with a carboxy-terminal assay. No significant changes in serum calcium, phosphate and alkaline phosphatase were noted after treatment with either agent, but serum concentrations of osteocalcin increased significantly. We conclude the H2-receptor antagonists do not favourably influence the natural history of hyperparathyroid bone disease in patients with end-stage chronic renal failure.
我们评估了雷尼替丁和西咪替丁（组胺H2受体拮抗剂）对22例终末期慢性肾衰竭患者血清甲状旁腺激素（PTH）浓度的影响。治疗3个月后，通过针对PTH分子中部的放射免疫测定法测定，血清PTH浓度显著降低。相比之下，使用针对氨基末端部分的测定法时，PTH浓度显著升高，而使用羧基末端测定法时则未观察到变化。使用这两种药物治疗后，血清钙、磷和碱性磷酸酶均无显著变化，但骨钙素的血清浓度显著升高。我们得出结论，H2受体拮抗剂对终末期慢性肾衰竭患者甲状旁腺骨病的自然病程没有有利影响。
